ViroPharma files for pleconaril approval

1 August 2001

ViroPharma has applied to the US Food and Drug Administration forapproval to market Picovir (pleconaril), its antiviral intended as a treatment for adults with viral respiratory infections (colds) caused by picornaviruses. The filing is a major achievement for the drug, which was all but written off last year after it achieved disappointing results in three successive clinical trials (Marketletter April 17, 2000)

Earlier this year, the company reported positive results from two Phase III trials of the drug, which showed that it had an effect on symptoms within 24 hours and reduced by approximately one day the time to resolution of symptoms (Marketletter March 26). Additional studies are planned looking at the drug's use in children and in the prevention of colds.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.